Neurobiological Adds VP From Eisai
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurobiological Technologies has named former Eisai Medical Research international project team leader David Levy, MD, to the newly created post of VP- clinical development.
You may also be interested in...
Neurobiological To Revive Viprinex Stroke Trials Following Empire Acquisition
New Phase III trials for Abbott's former anticoagulant will be based on meta-analyses of previous Phase II and III trials of the pit viper venom-derived agent, Neurobiological Technologies says. Empire licensed Viprinex from Abbott in 2002.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.